Your browser doesn't support javascript.
loading
Protocol for harmonization of randomized trials testing the addition of behavioral therapy to buprenorphine for opioid use disorder.
McHugh, R Kathryn; Bailey, Allen J; Weiss, Roger D; Fitzmaurice, Garrett M.
Affiliation
  • McHugh RK; McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.
  • Bailey AJ; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
  • Weiss RD; McLean Hospital, 115 Mill Street, Belmont, MA 02478, United States.
  • Fitzmaurice GM; Department of Psychiatry, Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, United States.
Drug Alcohol Depend Rep ; 11: 100226, 2024 Jun.
Article in En | MEDLINE | ID: mdl-38545409
ABSTRACT

Background:

Although buprenorphine is an effective treatment for opioid use disorder (OUD), much remains to be understood about treatment non-response and methods for improving treatment retention. The addition of behavioral therapies to buprenorphine has not yielded consistent benefits for opioid outcomes, on average. However, several studies suggest that certain subgroups may benefit from the combination of buprenorphine and behavioral therapy, highlighting the potential for personalized approaches to treatment. Furthermore, little is known about whether behavioral therapies improve buprenorphine retention or non-opioid (e.g., functional) outcomes.

Methods:

The objective of this project is to harmonize four previously conducted clinical trials testing the addition of behavioral therapy to buprenorphine maintenance for OUD and to use this larger dataset to answer critical clinical questions about the role of behavioral therapy in this population. Study aims include identifying potential moderators of the effect of the addition of behavioral therapy and quantifying the effect of behavioral therapy on buprenorphine retention and functional outcomes.

Results:

Analyses will consider outcomes of weeks of opioid use, weeks of retention in buprenorphine treatment, and functional outcomes as measured by the Addiction Severity Index. Analyses will include an indicator for each study to account for heterogeneity of samples and design.

Conclusion:

Results will help to inform clinical and research efforts to optimize the use of behavioral therapies in the treatment of OUD.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drug Alcohol Depend Rep Year: 2024 Document type: Article Country of publication: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Drug Alcohol Depend Rep Year: 2024 Document type: Article Country of publication: Países Bajos